Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Nasopharyngeal Carcinoma 11Squamous Cell Carcinoma of Head and Neck 9Small Cell Lung Carcinoma 9Uterine Cervical Neoplasms 7Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Esophageal Squamous Cell Carcinoma 5Cholangiocarcinoma 5Lung Neoplasms 4Head and Neck Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Neoplasms 3Endometrial Neoplasms 3Ovarian Neoplasms 2Neoplasms 2NSCLC 2Esophageal Neoplasms 2Breast Neoplasms 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Tongue Squamous Cell Carcinoma 1Thyroid Neoplasms 1Thymoma 1Thymic epithelial tumor 1Solid Tumor Cancer 1Recurrence 1Rare Tumour 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Trastuzumab 3Oxaliplatin 3Capecitabine 2disitamab vedotin 1Tegafur 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × HER2-positive Gastric Cancer × Cisplatin × Clear all
NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡